1 / 18

Your name EFA Board Member Your email address www.efanet.org

Need for political innovations and actions to control respiratory allergies equally in all parts of Europe. Your name EFA Board Member Your email address www.efanet.org. The European Federation of Allergy and Airways Diseases Patients Associations, EFA.

loring
Download Presentation

Your name EFA Board Member Your email address www.efanet.org

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Need for political innovations and actions to control respiratory allergies equally in all parts of Europe Your name EFA Board Member Your email address www.efanet.org

  2. The European Federation of Allergy and Airways Diseases Patients Associations, EFA • EFA is a network of allergy asthma and COPD patients associations from across Europe • Founded in 1991 • Dedicated to improve the health and quality of life for patients and their families by facilitating collaboration and sharing knowledge and experiences • Objective to make Europe a place where people with allergy, asthma and COPD: • Have the right to best quality of care and safeenvironment • Live uncompromised lives • Are actively involved in decisions influencing their health • www.efanet.org

  3. Respiratory Allergies, a Public Health Problem 25% • The most common chronic diseases in Europe • 113 million people suffer from allergic rhinitis • 68 million from allergic asthma in the EU • They severely affect the Quality of Life of sufferers, care-givers and families • They have a major impact on work/school performance and productivity, and economic burden • Approximately 45% of patients have never received a diagnosis in the health care of allergic rhinitis sufferers among the population1 15-20% of allergic rhinitis sufferers have severe symptoms2 1. Bauchau V., Durham S.R., EurRespir J 2004:758-764 2. White P. et al. Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy? Clinical and Experimental Allergy. 1998: 28: 266-270

  4. Respiratory Allergies are insufficiently takeninto consideration • There is low awareness about allergic diseases among authorities, the public and even among patients • Respiratory allergies are often: • underestimated, • underdiagnosed, • undertreated • The role of allergic rhinitis in asthma is not understood • 20% to 40% of AR patients have asthma • 80% of asthmatic patients suffer from allergic rhinitis • Allergicrhinitis multiplies by 4 to 10 the risk to developasthma

  5. AllergicRhinitis impairs the workingcapacity: Costs are twicethose of migraine or depression † 593 Allergic rhinitis 518 High stress 277 Migraine 273 Depression 269 Arthritis/rheumatism 248 Anxiety disorder 181 RI 105 Hypertension or high BP 95 Diabetes 85 Asthma 40 Coronary heart disease 0 100 200 300 400 500 600 Mean productivity loss per employee, per year ($) †P<0.05 for allergic rhinitis/hay fever vs other conditions. Lamb et al. Curr Med Res Opin. 2006

  6. Everyfourthworking patient took time offwork due to allergicrhinitis Valovirta E, Palkonen S, Myrseth E. RespiratoryMedicine 2206

  7. Everythirdstudying patient took time offschool due to allergicrhinitis Valovirta E, Palkonen S, Myrseth E. RespiratoryMedicine 2206

  8. Purpose of EFA Respiratory Allergy Awareness Project2011 -2014 • Improve awareness of respiratory allergies and relieve the burden to Patients, physicians, nurses, and Policy Makers • Call European policy makers for rapid action in respiratory allergies • Favor access to early diagnosis and proper treatment • Increase access to and reimbursement of allergen immunotherapy • Decrease inequalities of access to the only treatment influensing the mechanisms of respiratory allergies

  9. EFA RespiratoryAllergyAwareness Project 2011 -2014: A survey in 18 EU countries, from Patients to Patients • Development and Dissemination of A Surveyamongst EFA members, « A survey from Patients to Patients » • EFA membersfrom 18 countries answered the surveyrepresenting414 million people in Europe • Production and Publication of « EFA Book on Respiratory Allergies, RaiseAwareness, Relieve the Burden» • Available in 15 Europeanlanguages • sent to all MEPs • LuncheonDebate on Respiratory Allergies including « Call to Action » in European Parliament 22 Nov. 2011

  10. Call to Action: RaiseAwareness, Relieve the Burden We call upon European policy-makers to coordinate actions to • Increase political recognition of respiratory allergies as a real and serious disease • Promote national programmes on respiratory allergies • Prioritize the prevention, management and control of respiratory allergies • Promote training in allergyfor healthcare professionals to improve an accurate and early diagnosis • Align healthcare and reimbursement policies to support appropriate disease management • Improve air quality

  11. Finnish Asthma Programme 1994-2004New patients, disability pensions and rehabilitation Number of asthmatics still slightly growing, Allergy Programme aims to reverse the trend Absolute decrease in disability 76% Haahtela T, et al. Thorax 2006

  12. Finnish Asthma Programme 1994-2004 A rapid decrease of hospital days and mortality Haahtela T, et al. Thorax 2006

  13. Finnish Asthma Programme 1994-2004 Asthma costs in Finland 1987-2007 Reissell E, et al. Asthma costs in Finland. A public health model to indicate cost effectiveness during 20 years. Finnish Medical Journal 2010.

  14. Finnish Allergy Programme 2008-2018 • A comprehensive plan to reduce the burden of allergies and asthma • The aims are: • To increase immunological tolerance • To change attitudes to support health instead of medicalizing common and mild allergy symptoms • To use the resources for patients with more severe allergic diseases • To support ALLERGY HEALTH whichmeansgoodphysical, social and psychologicalhealthregardless the allergicdisease

  15. Treatment of allergic rhinoconjunctivitis according ARIA, Allergic Rhinitis and its Impact on Asthma by WHO moderate severe persistent mild persistent moderate severe intermittent mild Intermittent Nasalsteroids Nasalcromones Oral and local antihistamine Oral and local decongestants for short time only Allergenavoidancewhenappropriate Allergen immunotherapy

  16. Allergen immunotherapy (AIT),a specific and etiological treatment • Allergen immunotherapy consists in re-educating patient’s immune system by administering the natural allergen that causes the allergy • Allergen immunotherapy alters the natural course of the disease • Influences on the IgE-mediated inflammation as a whole             16

  17. Allergen immunotherapy (AIT),a specific and etiological treatment • Allergen immunotherapy consists in re-educating patient’s immune system by administering the natural allergen that causes the allergy • Allergen immunotherapy alters the natural course of the disease having disease modifying efficacy (endorsed by EMA) • Influences on the IgE-mediated inflammation as a whole             17

  18. How decision makers can play a role? • Promoting Allergy Education • Medical and nursing schools • GPs • Allergy Specialist Education • Founding more National Allergy Centres • Decreasing inequalities by favoring better and equal reimbursement policies

More Related